AACI Commends House Passage of Revised 21st Century Cures Act

By a roll call vote of 392-26, the U.S. House of Representatives on November 30 passed a revised version of the 21st Century Cures Act, which provides $1.8 billion for cancer research. The bipartisan bill is headed to the Senate for a final vote. AACI leaders sent a letter to House and Senate leadership the day before the vote, asking that Congress complete work on the 21st Century Cures Act before the 114th Congress concludes.

“The nation’s cancer centers applaud the bipartisan work that led to the passage of the 21st Century Cures Act in the House," said AACI Executive Director Barbara Duffy Stewart. "This bill is the most significant piece of legislation for patients fighting cancer in the 21st Century and ensures that advances in cancer prevention, diagnosis, treatment and care are within reach like never before.”

“We welcome the increased federal investment in cancer research,” said AACI President Dr. Stanton Gerson. “Investing in the NIH and NCI not only plays a vital role in addressing cancer incidence, but it also contributes to curbing the overall costs associated with cancer.”

Any new funding in the landmark legislation will be fully offset and will be in addition to what otherwise can be appropriated to the NIH. Funding highlights in the 21st Century Cures Act include $4.8 billion for the National Institutes of Health over the next 10 years, including $1.8 billion for cancer research, which would be distributed between fiscal years 2017 and 2023.

The legislation will be considered in the senate the week of December 5.